

# Lana Chahine

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8388445/publications.pdf>

Version: 2024-02-01

70  
papers

3,029  
citations

201575

27  
h-index

182361

51  
g-index

74  
all docs

74  
docs citations

74  
times ranked

3784  
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on treatments for nonmotor symptoms of Parkinson's diseaseâ€”an evidenceâ€based medicine review. <i>Movement Disorders</i> , 2019, 34, 180-198.	2.2	619
2	The Parkinson's progression markers initiative (PPMI) â€ establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
3	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018, 33, 771-782.	2.2	136
4	The Effect of the COVID-19 Pandemic on People with Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1365-1377.	1.5	114
5	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
6	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	2.2	104
7	Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 102-106.	1.1	99
8	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	4.9	94
9	Effects of STN DBS for Parkinsonâ€™s disease on restless legs syndrome and other sleep-related measures. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 208-211.	1.1	91
10	In vivo distribution of $\alpha$ -synuclein in multiple tissues and biofluids in Parkinson disease. <i>Neurology</i> , 2020, 95, e1267-e1284.	1.5	91
11	Longitudinal analyses of cerebrospinal fluid $\alpha$ -synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1354-1364.	2.2	89
12	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinsonâ€™s disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 78-88.	0.9	85
13	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020, 88, 574-587.	2.8	55
14	Palliative care needs of patients with neurologic or neurosurgical conditions. <i>European Journal of Neurology</i> , 2008, 15, 1265-1272.	1.7	54
15	Self-reported physical activity levels and clinical progression in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 118-125.	1.1	53
16	The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2017, 11, 359-368.	0.6	50
17	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Crossâ€Sectional Study. <i>Movement Disorders</i> , 2020, 35, 833-844.	2.2	48
18	Treatment of Sleep Dysfunction in Parkinsonâ€™s Disease. <i>Current Treatment Options in Neurology</i> , 2017, 19, 26.	0.7	44

#	ARTICLE	IF	CITATIONS
19	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 449-461.	1.7	44
20	Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 246.	1.7	43
21	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinson's Disease</i> , 2019, 5, 7.	2.5	40
22	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1640-1645.	2.2	39
23	Dopamine transporter imaging predicts clinically defined $\alpha$ -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 201-212.	1.7	37
24	Corticobasal syndrome. <i>Neurology: Clinical Practice</i> , 2014, 4, 304-312.	0.8	36
25	$\epsilon$ -APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	2.2	35
26	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	1.1	33
27	Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 793-802.	0.9	32
28	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , 2020, 35, 1618-1625.	2.2	31
29	Dementia and depression among nursing home residents in Lebanon: a pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 283-285.	1.3	29
30	Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning. <i>The Lancet Digital Health</i> , 2021, 3, e555-e564.	5.9	29
31	Du rire aux larmes: Pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine. <i>Epilepsy and Behavior</i> , 2006, 8, 610-615.	0.9	25
32	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. <i>Journal of Parkinson's Disease</i> , 2020, 10, 665-675.	1.5	25
33	Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder. <i>Npj Parkinson's Disease</i> , 2019, 5, 2.	2.5	24
34	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's disease patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	1.7	23
35	Cognitive behavioral therapy for insomnia in Parkinson's disease: a case series. <i>Npj Parkinson's Disease</i> , 2017, 3, 25.	2.5	22
36	Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for $\alpha$ -Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). <i>Journal of Parkinson's Disease</i> , 2018, 8, 517-527.	1.5	16

#	ARTICLE	IF	CITATIONS
37	Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 796-805.	0.8	15
38	Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. <i>Journal of Parkinson's Disease</i> , 2019, 9, 665-679.	1.5	15
39	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	1.1	15
40	Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. <i>Journal of Parkinson's Disease</i> , 2020, 10, 677-691.	1.5	15
41	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	1.5	13
42	The Most Bothersome Aspects of Off Periods Reported by Individuals with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 284-292.	0.8	11
43	Contribution of neuropsychiatric symptoms in Parkinson's disease to different domains of caregiver burden. <i>Journal of Neurology</i> , 2021, 268, 2961-2972.	1.8	10
44	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1972-1978.	2.2	10
45	Clinical Reasoning: Cerebral cavernous malformations. <i>Neurology</i> , 2009, 73, e44-9.	1.5	9
46	Triggers and alleviating factors for fatigue in Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0245285.	1.1	9
47	Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East. <i>Journal of Parkinson's Disease</i> , 2020, 10, 729-741.	1.5	8
48	Diffusion Tensor Imaging of the Olfactory System in Older Adults With and Without Hyposmia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 648598.	1.7	8
49	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. <i>Acta Neuropathologica Communications</i> , 2022, 10, 21.	2.4	8
50	The experience of care partners of patients with Parkinson's disease psychosis. <i>PLoS ONE</i> , 2021, 16, e0248968.	1.1	7
51	Revision of Diagnosis in Early Parkinsonism with Abnormal Dopamine Transporter Imaging. <i>Journal of Parkinson's Disease</i> , 2019, 9, 327-334.	1.5	6
52	Regional Gray Matter Volume Links Rest-Activity Rhythm Fragmentation With Past Cognitive Decline. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 248-251.	0.6	6
53	Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	0.8	5
54	Portable objective assessment of upper extremity motor function in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 61-66.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Understanding the Lexicon of Fatigue in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1185-1193.	1.5	4
56	Knowledge, Responsibilities, and Peer Advice From Care Partners of Patients With Parkinson Disease Psychosis. <i>Frontiers in Neurology</i> , 2021, 12, 633645.	1.1	4
57	Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 76-81.	0.8	3
58	Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1276-1277.	2.2	2
59	Use of Figurative Language by People With Parkinson Disease to Describe "Off" Periods. <i>Neurology: Clinical Practice</i> , 2021, 11, e462-e471.	0.8	2
60	Mild Parkinsonian Signs, Energy Decline, and Striatal Volume in Community-Dwelling Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 800-806.	1.7	2
61	The Experience of OFF Periods in Parkinson's Disease: Descriptions, Triggers, and Alleviating Factors. <i>Journal of Patient-centered Research and Reviews</i> , 2021, 8, 232-238.	0.6	2
62	Surveying Global Availability of Parkinson's Disease Treatment. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1023-1034.	1.5	2
63	Sleep and circadian rhythms in the treatment, trajectory, and prevention of neurodegenerative disease. <i>Neurobiology of Disease</i> , 2020, 145, 105075.	2.1	1
64	Topographic disorientation following mesial left temporo-occipital hemorrhage. <i>Neurology: Clinical Practice</i> , 2013, 3, 84-85.	0.8	0
65	Reply to Comment on: The Most Bothersome Aspects of off Periods Reported by Individuals with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 879-880.	0.8	0
66	Author Response: In Vivo Distribution of $\alpha$ -Synuclein in Multiple Tissues and Biofluids in Parkinson Disease. <i>Neurology</i> , 2021, 96, 965-967.	1.5	0
67	Nocturnal psychosis. , 2020, , 35-45.		0
68	Hyposmia and Neuroimaging Signature in Community-Dwelling Older Adults. <i>Innovation in Aging</i> , 2020, 4, 530-530.	0.0	0
69	Restless legs syndrome and periodic limb movements. , 2020, , 77-87.		0
70	REM sleep behavior disorder in Parkinson's disease. , 2020, , 47-60.		0